Titre : Empreinte moléculaire

Empreinte moléculaire : Questions médicales fréquentes

Termes MeSH sélectionnés :

Platelet Transfusion
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Empreinte moléculaire : Questions médicales les plus fréquentes", "headline": "Empreinte moléculaire : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Empreinte moléculaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-24", "dateModified": "2025-03-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Empreinte moléculaire" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Techniques de chimie synthétique", "url": "https://questionsmedicales.fr/mesh/D060326", "about": { "@type": "MedicalCondition", "name": "Techniques de chimie synthétique", "code": { "@type": "MedicalCode", "code": "D060326", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.897.836.249" } } }, "about": { "@type": "MedicalCondition", "name": "Empreinte moléculaire", "alternateName": "Molecular Imprinting", "code": { "@type": "MedicalCode", "code": "D054802", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Zhimin Liu", "url": "https://questionsmedicales.fr/author/Zhimin%20Liu", "affiliation": { "@type": "Organization", "name": "Faculty of Science, Kunming University of Science and Technology, Kunming 650500, China. Electronic address: lab_chem@126.com." } }, { "@type": "Person", "name": "Alessandra Maria Bossi", "url": "https://questionsmedicales.fr/author/Alessandra%20Maria%20Bossi", "affiliation": { "@type": "Organization", "name": "Department of Biotechnology, University of Verona, Strada Le Grazie 15, Verona 37134, Italy." } }, { "@type": "Person", "name": "Jinhua Li", "url": "https://questionsmedicales.fr/author/Jinhua%20Li", "affiliation": { "@type": "Organization", "name": "CAS Key Laboratory of Coastal Environmental Processes and Ecological Remediation, Shandong Key Laboratory of Coastal Environmental Processes, Research Center for Coastal Environmental Engineering and Technology, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China." } }, { "@type": "Person", "name": "Xian Liu", "url": "https://questionsmedicales.fr/author/Xian%20Liu", "affiliation": { "@type": "Organization", "name": "School of Urban Construction, Wuhan University of Science and Technology, Wuhan, 430065, China." } }, { "@type": "Person", "name": "Lei Zhu", "url": "https://questionsmedicales.fr/author/Lei%20Zhu", "affiliation": { "@type": "Organization", "name": "School of Urban Construction, Wuhan University of Science and Technology, Wuhan, 430065, China. 200844529@qq.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes.", "datePublished": "2023-07-15", "url": "https://questionsmedicales.fr/article/37452616", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/ejh.14049" } }, { "@type": "ScholarlyArticle", "name": "The appropriateness of platelet transfusions in hematological patients and the potential for improvement.", "datePublished": "2022-12-07", "url": "https://questionsmedicales.fr/article/36493919", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.tracli.2022.11.007" } }, { "@type": "ScholarlyArticle", "name": "Acute hemolytic transfusion reaction following ABO-mismatched platelet transfusion: Two case reports.", "datePublished": "2023-02-15", "url": "https://questionsmedicales.fr/article/36805153", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.transci.2023.103658" } }, { "@type": "ScholarlyArticle", "name": "Evaluation of the Association of Platelet Count, Mean Platelet Volume, and Platelet Transfusion With Intraventricular Hemorrhage and Death Among Preterm Infants.", "datePublished": "2022-10-03", "url": "https://questionsmedicales.fr/article/36260331", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1001/jamanetworkopen.2022.37588" } }, { "@type": "ScholarlyArticle", "name": "Immunologic effects of red blood cell and platelet transfusions in neonates.", "datePublished": "2022-09-21", "url": "https://questionsmedicales.fr/article/36165536", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MOH.0000000000000736" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Technologie, industrie et agriculture", "item": "https://questionsmedicales.fr/mesh/D013676" }, { "@type": "ListItem", "position": 3, "name": "Technologie", "item": "https://questionsmedicales.fr/mesh/D013672" }, { "@type": "ListItem", "position": 4, "name": "Technologie pharmaceutique", "item": "https://questionsmedicales.fr/mesh/D013678" }, { "@type": "ListItem", "position": 5, "name": "Techniques de chimie synthétique", "item": "https://questionsmedicales.fr/mesh/D060326" }, { "@type": "ListItem", "position": 6, "name": "Empreinte moléculaire", "item": "https://questionsmedicales.fr/mesh/D054802" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Empreinte moléculaire - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Empreinte moléculaire", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Empreinte moléculaire", "description": "Comment l'empreinte moléculaire est-elle utilisée en diagnostic ?\nQuels tests utilisent l'empreinte moléculaire ?\nL'empreinte moléculaire peut-elle identifier des pathogènes ?\nQuels types d'échantillons sont analysés ?\nL'empreinte moléculaire est-elle précise ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Platelet+Transfusion&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Empreinte moléculaire", "description": "Quels symptômes peuvent être détectés par empreinte moléculaire ?\nL'empreinte moléculaire peut-elle détecter des allergies ?\nPeut-on utiliser l'empreinte pour des maladies auto-immunes ?\nQuels biomarqueurs sont liés aux maladies cardiovasculaires ?\nL'empreinte moléculaire peut-elle aider au diagnostic précoce ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Platelet+Transfusion&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Empreinte moléculaire", "description": "Comment l'empreinte moléculaire aide-t-elle à la prévention des maladies ?\nPeut-on utiliser l'empreinte pour des dépistages réguliers ?\nL'empreinte moléculaire peut-elle aider à la vaccination ?\nQuels programmes de santé utilisent l'empreinte moléculaire ?\nL'empreinte moléculaire peut-elle réduire les épidémies ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Platelet+Transfusion&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Empreinte moléculaire", "description": "L'empreinte moléculaire est-elle utilisée en thérapie ?\nComment l'empreinte moléculaire aide-t-elle en pharmacologie ?\nPeut-on créer des vaccins avec l'empreinte moléculaire ?\nL'empreinte moléculaire aide-t-elle à la délivrance de médicaments ?\nQuels traitements peuvent bénéficier de l'empreinte moléculaire ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Platelet+Transfusion&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Empreinte moléculaire", "description": "Quelles complications peuvent survenir avec l'empreinte moléculaire ?\nL'empreinte moléculaire peut-elle causer des effets secondaires ?\nComment minimiser les complications liées à l'empreinte ?\nLes complications affectent-elles la fiabilité des tests ?\nQuelles sont les limites de l'empreinte moléculaire ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Platelet+Transfusion&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Empreinte moléculaire", "description": "Quels facteurs influencent l'efficacité de l'empreinte moléculaire ?\nL'âge est-il un facteur de risque pour l'empreinte moléculaire ?\nLes maladies préexistantes affectent-elles l'empreinte ?\nLe mode de vie influence-t-il les résultats de l'empreinte ?\nLes médicaments peuvent-ils interférer avec l'empreinte moléculaire ?", "url": "https://questionsmedicales.fr/mesh/D054802?mesh_terms=Platelet+Transfusion&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment l'empreinte moléculaire est-elle utilisée en diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet de détecter des biomolécules spécifiques dans des échantillons biologiques." } }, { "@type": "Question", "name": "Quels tests utilisent l'empreinte moléculaire ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests immunologiques et chromatographiques pour identifier des analytes spécifiques." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle identifier des pathogènes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est utilisée pour détecter des virus et bactéries dans des échantillons cliniques." } }, { "@type": "Question", "name": "Quels types d'échantillons sont analysés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Sang, urine, salive et autres fluides biologiques peuvent être analysés." } }, { "@type": "Question", "name": "L'empreinte moléculaire est-elle précise ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle offre une haute sélectivité et sensibilité pour les cibles moléculaires." } }, { "@type": "Question", "name": "Quels symptômes peuvent être détectés par empreinte moléculaire ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des biomarqueurs associés à des maladies comme le cancer ou des infections." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle détecter des allergies ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut identifier des allergènes spécifiques dans des échantillons." } }, { "@type": "Question", "name": "Peut-on utiliser l'empreinte pour des maladies auto-immunes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle aide à détecter des auto-anticorps dans des maladies auto-immunes." } }, { "@type": "Question", "name": "Quels biomarqueurs sont liés aux maladies cardiovasculaires ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs comme la troponine peuvent être détectés par empreinte moléculaire." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle aider au diagnostic précoce ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle permet une détection précoce de biomarqueurs associés à des maladies." } }, { "@type": "Question", "name": "Comment l'empreinte moléculaire aide-t-elle à la prévention des maladies ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet de détecter des biomarqueurs de risque, facilitant des interventions précoces." } }, { "@type": "Question", "name": "Peut-on utiliser l'empreinte pour des dépistages réguliers ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est adaptée pour des dépistages réguliers de certaines maladies." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle aider à la vaccination ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut identifier des cibles pour le développement de nouveaux vaccins." } }, { "@type": "Question", "name": "Quels programmes de santé utilisent l'empreinte moléculaire ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des programmes de dépistage du cancer et de surveillance des infections." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle réduire les épidémies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle aide à identifier rapidement les agents pathogènes lors d'épidémies." } }, { "@type": "Question", "name": "L'empreinte moléculaire est-elle utilisée en thérapie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle est principalement utilisée pour le diagnostic, mais peut guider des traitements." } }, { "@type": "Question", "name": "Comment l'empreinte moléculaire aide-t-elle en pharmacologie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elle permet de concevoir des médicaments ciblant des molécules spécifiques." } }, { "@type": "Question", "name": "Peut-on créer des vaccins avec l'empreinte moléculaire ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être utilisée pour développer des vaccins ciblant des pathogènes." } }, { "@type": "Question", "name": "L'empreinte moléculaire aide-t-elle à la délivrance de médicaments ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut améliorer la délivrance ciblée de médicaments dans l'organisme." } }, { "@type": "Question", "name": "Quels traitements peuvent bénéficier de l'empreinte moléculaire ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements pour le cancer, les infections et les maladies métaboliques." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'empreinte moléculaire ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des faux positifs ou négatifs peuvent survenir, affectant le diagnostic." } }, { "@type": "Question", "name": "L'empreinte moléculaire peut-elle causer des effets secondaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle est une méthode d'analyse et ne cause pas d'effets secondaires directs." } }, { "@type": "Question", "name": "Comment minimiser les complications liées à l'empreinte ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "En utilisant des protocoles standardisés et en validant les méthodes de détection." } }, { "@type": "Question", "name": "Les complications affectent-elles la fiabilité des tests ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications peuvent réduire la fiabilité des résultats des tests." } }, { "@type": "Question", "name": "Quelles sont les limites de l'empreinte moléculaire ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les limites incluent la spécificité et la sensibilité, pouvant varier selon les cibles." } }, { "@type": "Question", "name": "Quels facteurs influencent l'efficacité de l'empreinte moléculaire ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "La nature de la molécule cible et les conditions de synthèse des polymères." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour l'empreinte moléculaire ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'âge peut influencer la concentration de biomarqueurs dans les échantillons." } }, { "@type": "Question", "name": "Les maladies préexistantes affectent-elles l'empreinte ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent modifier les niveaux de biomarqueurs détectés par empreinte." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il les résultats de l'empreinte ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs comme l'alimentation et l'exercice peuvent affecter les biomarqueurs." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils interférer avec l'empreinte moléculaire ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent altérer les niveaux de biomarqueurs dans les tests." } } ] } ] }

Sources (7085 au total)

Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes.

This study aimed to describe the burden of thrombocytopenia, supportive care practices, bleeding complications and predictors of bleeding in MDS patients within a large Australian hospital network, to... A retrospective cohort study of patients aged ≥18 years with MDS, chronic myelomonocytic leukaemia or MDS/myeloproliferative overlap neoplasm admitted from 2016 to 2018 was conducted. Data were obtain... One hundred seventy-nine patients (median age 78 years, 61.5% male) were identified. The median platelet count at first admission was 90 × 10... Thrombocytopenia is common in MDS. Although guidelines recommend otherwise, prophylactic platelet transfusions were commonly used for severe thrombocytopenia. Despite the majority of patients receivin...

The appropriateness of platelet transfusions in hematological patients and the potential for improvement.

Hematology patients are intensive platelet users. In clinical practice, a substantial proportion of platelet (PLT) transfusions are routinely administered outside the guidelines despite compelling evi... The audit of all PLT orders for adult hematological inpatients was conducted over 2 months. The assessment was performed using guidelines for PLT transfusion. Patient demographic, clinical, and transf... Based on 286 PLT orders, 344 PCs were transfused to 67 patients: 235 (82.2%) prophylactical due to low PLT count, 34 (11.9%) preprocedural and 17 (5.9%) therapeutic. Overall, 105 (36.77%) PLT transfus... Our audit of PLT transfusion practice found a large proportion of inappropriate PLT transfusions. Based on the most common deviations from the guidelines a variety of targeted measures for improvement...

Evaluation of the Association of Platelet Count, Mean Platelet Volume, and Platelet Transfusion With Intraventricular Hemorrhage and Death Among Preterm Infants.

Platelet transfusion is commonly performed in infants to correct severe thrombocytopenia or prevent bleeding. Exploring the associations of platelet transfusion, platelet count (PC), and mean platelet... To evaluate the associations of platelet transfusion, PC, and MPV with IVH and in-hospital mortality and to explore whether platelet transfusion-associated IVH and mortality risks vary with PC and MPV... This retrospective cohort study included preterm infants who were transferred to the neonatal intensive care unit on their day of birth and received ventilation during their hospital stay. The study w... Platelet transfusion, PC, and MPV.... Any grade IVH, severe IVH (grade 3 or 4), and in-hospital mortality.... Among the 1221 preterm infants (731 [59.9%] male; median [IQR] gestational age, 31.0 [29.0-33.0] weeks), 94 (7.7%) received 166 platelet transfusions. After adjustment for potential confounders, plate... In preterm infants, platelet transfusion, PC, and MPV were associated with mortality, and PC was also associated with any grade IVH and severe IVH. The findings suggest that a lower platelet transfusi...

Immunologic effects of red blood cell and platelet transfusions in neonates.

Premature neonates are frequently transfused red blood cells (RBCs) or platelets to raise hemoglobin or platelet counts. However, these transfusions may have unintended effects on the immune system. T... Neonatal RBC transfusions are associated with increases in plasma pro-inflammatory cytokines, but recent findings suggest sex-specific differential responses. At least one cytokine (monocyte chemoattr... RBC and platelet transfusions alter neonatal immune and inflammatory responses. Their pro-inflammatory effects might worsen neonatal disease or affect neurodevelopmental outcomes....

Thromboelastography in guiding preventive platelet transfusion in patients with haematologic diseases.

This study analysed the relationships between the main thromboelastography (TEG) parameters, the platelet (PLT) count and clinical bleeding in patients with blood diseases. We explored the threshold o... In total, 268 patients with clear diagnoses of blood diseases and thrombocytopenia were enrolled and divided into five groups, A, B, C, D and E, corresponding to PLT counts of 0-10 × 10... The maximum amplitude (MA) in groups A, B and C increased gradually, with a significant difference between each pair of these groups (P < 0.05). In groups A, B, C, D and E, the corresponding MA at the... The MA can be used as a reference indicator for preventive PLT transfusion to a certain extent. When the PLT count is within different ranges, the MA threshold for preventive PLT transfusion also diff...

Platelet transfusion in critical care: A new method to analyze transfusion practice based on decision time intervals.

While prior studies of platelet transfusion in critical care have focused on transfusions given, proper analysis of clinical transfusion practice also requires consideration of the decision not to tra... We introduce a new method to assess transfusion practice based on decision time intervals (DTIs). Each patient's intensive care (ICU) stay was segmented into a series of DTIs defined by a time interva... Among 6125 ICU patients treated between October 2016 and October 2021, we analyzed 39,745 DTIs among patients (n = 2921) who had at least one DTI with thrombocytopenia (≤150,000/μL). We found no assoc... DTI analysis represents a new method to assess transfusion practice that considers both transfusions given and not given, and that analyzes clinical circumstances present when decisions regarding tran...

A meta-analysis of risk factors associated with platelet transfusion refractoriness.

Platelet transfusion refractoriness (PTR) remains an intractable issue in clinical practice, and is common in hematological patients. At present, it is believed that both immune and non-immune factors... PubMed, Embase, Cochrane library, and Web of Science were selected as research database platforms. Citations included were further assessed for quality and bias using the Newcastle-Ottawa Scale. All a... The preliminary search revealed 1069 publications, and 17 (5929 patients in total) were ultimately included in the quantitative analysis. The following variables were associated with the occurrence of... We identified some important risk factors for PTR, but further research is needed to identify the many other possible elements that may contribute to or mediate PTR....